ABCA7 (ATP-Binding Cassette Transporter A7)

Migration, Crosslink

📖

ABCA7 (ATP-Binding Cassette Transporter A7)

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-abca7

📖 Wiki Page

gene2588 wordssynced 2026-04-02

ABCA7 (ATP-Binding Cassette Transporter A7)

| Property | Value | [@hollingworth2011]
|----------|-------| [@kim2019]
| Gene Symbol | ABCA7 | [@aikawa2018]
| Full Name | ATP-Binding Cassette Transporter A7 | [@klein2020]
| Chromosomal Location | 19p13.3 | [@vasquez2020]
| NCBI Gene ID | 10347 | [@satoh2015]
| OMIM ID | 605414 | [@chan2018]
| Ensembl ID | ENSG00000064687 | [@fu2021]
| UniProt ID | Q9NP71 | [@reitz2020]
| Encoded Protein | ATP-binding cassette subfamily A member 7 | [@sassi2018]
| Associated Diseases | Alzheimer's disease, Spastic Paraplegia | [@nordestgaard2017]

</div>

Pathway Diagram

...

ABCA7 (ATP-Binding Cassette Transporter A7)

| Property | Value | [@hollingworth2011]
|----------|-------| [@kim2019]
| Gene Symbol | ABCA7 | [@aikawa2018]
| Full Name | ATP-Binding Cassette Transporter A7 | [@klein2020]
| Chromosomal Location | 19p13.3 | [@vasquez2020]
| NCBI Gene ID | 10347 | [@satoh2015]
| OMIM ID | 605414 | [@chan2018]
| Ensembl ID | ENSG00000064687 | [@fu2021]
| UniProt ID | Q9NP71 | [@reitz2020]
| Encoded Protein | ATP-binding cassette subfamily A member 7 | [@sassi2018]
| Associated Diseases | Alzheimer's disease, Spastic Paraplegia | [@nordestgaard2017]

</div>

Pathway Diagram

Mermaid diagram (expand to render)

Overview

ABCA7 is a human gene whose product aBCA7** encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis. Variants in ABCA7 have been implicated in Alzheimer's Disease (AD), Spastic Paraplegia. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

Function

ABCA7 encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis.

Key normal physiological functions include:

Lipid efflux - Mediates transport of lipids to apolipoproteins
Phospholipid transport - Transfers phospholipids across cellular membranes
Cholesterol homeostasis - Regulates cellular cholesterol levels
Immune function - Modulates macrophage and microglial responses
Phagocytosis - Involved in cellular clearance mechanisms
[Blood-brain barrier](/entities/blood-brain-barrier) - May regulate endothelial cell function

The protein contains:

Two transmembrane domains - 12 transmembrane helices total
Two nucleotide-binding domains - ATP hydrolysis for transport
Regulatory domains - Control of transport activity

Disease Associations

Alzheimer's Disease (AD)

ABCA7 is a significant genetic risk factor for late-onset Alzheimer's disease:

GWAS have identified ABCA7 as an AD risk locus
Loss-of-function variants increase AD risk by approximately 1.5-fold
ABCA7 expression is reduced in AD brains

Pathogenic mechanisms linking ABCA7 to AD:

[Amyloid-beta](/proteins/amyloid-beta) clearance - ABCA7 affects cellular amyloid-beta efflux and degradation
Lipid metabolism - Alters brain lipid homeostasis
Neuroinflammation - Modulates microglial phagocytosis of amyloid plaques
[APOE](/proteins/apoe-protein) lipidation - Cooperates with ABCA1 in [APOE](/proteins/apoe-protein) lipidation
Synaptic function - May influence synaptic lipid composition

Spastic Paraplegia

Rare ABCA7 variants are associated with hereditary spastic paraplegia:

Loss-of-function mutations cause autosomal recessive spastic paraplegia
Characterized by progressive lower limb spasticity and weakness

Expression

ABCA7 is expressed primarily in immune cells and brain:

Highest expression: Bone marrow, spleen, thymus, lung
Moderate expression: Brain ([microglia](/cell-types/microglia), astrocytes), liver, kidney
Cellular localization: Plasma membrane, endoplasmic reticulum, lysosomes
Cell types: [Microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes), [neurons](/entities/neurons), macrophages, monocytes

In the brain, ABCA7 is particularly important in:

Microglial cells (phagocytic clearance)
Astrocytes (lipid homeostasis)
Neurons (synaptic function)

Allen Brain Atlas Data

Gene Expression

ABCA7 (ATP-Binding Cassette Transporter A7) shows microglial-enriched expression:

Microglia - Highest expression among brain cell types
Cerebral cortex - Moderate in neurons
Hippocampus - Moderate expression
White matter - High in oligodendrocytes

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

Microglia - Highest expression (especially in disease-associated microglia)
Macrophages - High expression in border-associated populations
Astrocytes - Moderate expression
Neurons - Lower expression

Brain Region Expression Levels

| Region | Expression Level | Data Source |
|--------|-----------------|--------------|
| Cortex | Medium-High | Human MTG |
| Hippocampus | Medium | Mouse Brain |
| White matter | High | Mouse Brain |
| Cerebellum | Low | Mouse Brain |

External Resources

[Allen Human Brain Atlas - ABCA7](https://human.brain-map.org/microarray/search/show?search_term=ABCA7)
[Allen Mouse Brain Atlas - ABCA7](https://mouse.brain-map.org/search/index.html?query=ABCA7)
[Allen Cell Type Atlas - ABCA7](https://celltypes.brain-map.org/)

Allen Brain Atlas Resources

ABCA7 expression data available from the Allen Brain Atlas:

[Human Brain Atlas - ABCA7 Expression](https://human.brain-map.org/microarray/search/show?search_term=ABCA7): Gene expression data across brain regions
[Allen Cell Type Atlas](https://celltypes.brain-map.org/): Cellular expression patterns in specific neuronal types
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/): Developmental expression patterns

Key Publications

[Hollingworth et al., Common variants in ABCA7, EPHA1, MS4A6A and CD33 (2011)](https://doi.org/10.1016/j.jalz.2011.01.004)

[Kim et al., ABCA7 deficiency impairs microglial function (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.004)

[Aikawa et al., ABCA7 and Alzheimer's disease (2018)](https://doi.org/10.1186/s13195-018-0363-3)

[Klein et al., ABCA7 and lipid metabolism in Alzheimer's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.07.015)

Cross-links

[ABCA7 Protein](/proteins/abca7-protein)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Alzheimer's Disease Genetics](/mechanisms/genetics)
[Microglia](/cell-types/microglia)
[Apolipoprotein E](/proteins/apoe-protein)

External Links

[Ensembl: ENSG00000064687](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064687)
[NCBI Gene: ABCA7](https://www.ncbi.nlm.nih.gov/gene/?term=ABCA7)
[GeneCards: ABCA7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCA7)
[OMIM: ABCA7](https://omim.org/search?search=ABCA7)
[Allen Brain Atlas: ABCA7](https://human.brain-map.org/microarray/search/show?search_term=ABCA7)

Detailed Protein Structure

ABCA7 is a member of the ATP-binding cassette (ABC) transporter superfamily, specifically the A subfamily (ABCA). The protein is composed of several functional domains that enable its role in lipid transport:

| Domain | Location | Function |
|--------|----------|----------|
| Nucleotide-Binding Domain 1 (NBD1) | N-terminal | ATP hydrolysis provides energy for transport |
| Nucleotide-Binding Domain 2 (NBD2) | C-terminal | ATP hydrolysis provides energy for transport |
| Transmembrane Domain 1 (TMD1) | Middle | Forms the translocation pore |
| Transmembrane Domain 2 (TMD2) | Middle | Forms the translocation pore |
| Regulatory Domain | Between NBDs | Controls transport activity |

The two NBDs each contain the characteristic Walker A (GXXXXGKST) and Walker B (hhhhDE) motifs, as well as the ABC signature (LSGGQ) motif. These domains work in concert to bind and hydrolyze ATP, coupling this energy to the conformational changes required for lipid translocation across cellular membranes.

The transmembrane domains consist of 12 α-helices that span the lipid bilayer, forming a channel through which lipids are transported. The substrate-binding site is thought to be located within the transmembrane domains, with specificity for various lipid species including phospholipids, cholesterol, and sphingolipids.

Mechanism of Lipid Transport

ABCA7 operates as an active transporter, using the energy from ATP hydrolysis to move lipids across cellular membranes against concentration gradients. The transport cycle involves several key steps:

Substrate binding: Lipids in the inner leaflet of the plasma membrane or in the cytosolic leaflet of intracellular membranes bind to ABCA7

ATP binding: ATP binds to both NBDs, inducing dimerization of the NBDs

Conformational change: NBD dimerization triggers a conformational change in the TMDs, opening the transporter on the opposite side of the membrane

Lipid release: The bound lipids are released into the extracellular space or into acceptor proteins

ATP hydrolysis: ATP hydrolysis causes NBD separation, resetting the transporter for another cycle

ABCA7 functions as a homodimer, with two ABCA7 proteins forming a functional transporter. The dimerization is stabilized by interactions between the NBDs and by disulfide bonds in the extracellular domains.

Lipid Efflux to ApoE

One of the critical functions of ABCA7 is facilitating lipid efflux to [apolipoprotein E](/genes/apoe) (ApoE), similar to the related transporter [ABCA1](/proteins/abca1-protein)[@vasquez2020]. This process is essential for:

ApoE lipidation: ABCA7 transfers lipids to lipid-free ApoE, converting it to a lipoparticle
Amyloid-beta clearance: Lipidated ApoE has enhanced capacity to bind and clear [amyloid-beta](/proteins/amyloid-beta) from the brain
Synaptic function: Lipidated ApoE supports synaptic integrity and function

The cooperation between ABCA7 and ABCA1 in ApoE lipidation suggests some functional redundancy, but ABCA7 has unique roles in brain-specific lipid homeostasis.

Genetic Variants and AD Risk

Common Variants

Genome-wide association studies (GWAS) have identified multiple common variants in ABCA7 that influence AD risk[@hollingworth2011]:

| Variant | Position | Risk Allele | Odds Ratio | Effect |
|---------|-----------|--------------|------------|--------|
| rs3764650 | Intron | G | 1.23 | Increased risk |
| rs4149268 | Intron | A | 1.15 | Increased risk |
| rs5987340 | Intron | G | 1.10 | Increased risk |

These variants are primarily located in intronic regions and are thought to affect ABCA7 expression or splicing rather than protein function.

Rare Variants

Rare loss-of-function variants in ABCA7 have a stronger effect on AD risk[@williams2019]:

LoF variants: Increase AD risk by approximately 1.5-2 fold
Frequency: ~1% of the population carries rare LoF variants
Mechanism: Complete loss of ABCA7 function impairs lipid transport
Ethnicity: More prevalent in African American populations[@sassi2018]

Population-Specific Effects

The effect of ABCA7 variants varies by ancestry:

European ancestry: Common and rare variants show consistent association
African American: Higher frequency of protective variants
East Asian: Different variant spectrum, some unique associations

ABCA7 and Microglial Function

Microglial Expression

ABCA7 is highly expressed in microglia, particularly in disease-associated microglia (DAM)[@kim2019]:

Expression level: Among the highest of ABC transporters in microglia
Localization: Primarily in plasma membrane and lysosomes
Regulation: Upregulated in response to amyloid pathology

Phagocytosis of Amyloid-Beta

ABCA7 plays a critical role in microglial phagocytosis[@stewart2021]:

Aβ recognition: Microglia recognize Aβ through various receptors (TREM2, CD33, TLRs)

Phagosome formation: ABCA7 localizes to phagosomes during Aβ engulfment

Lipid metabolism: ABCA7 regulates lipid composition of phagosomes

Lysosomal fusion: Proper lipid metabolism enables efficient lysosomal degradation

Antigen presentation: Lipid metabolism affects antigen presentation pathways

In ABCA7-deficient microglia:

Phagocytic capacity is reduced by 30-50%
Aβ accumulation in lysosomes is increased
Inflammatory responses are dysregulated
Migration toward Aβ plaques is impaired

Neuroinflammation

ABCA7 modulates neuroinflammation through lipid-mediated signaling:

Prostaglandin metabolism: ABCA7 affects lipid mediator production
Cytokine regulation: Lipid homeostasis influences cytokine expression
TREM2 connection: ABCA7 and TREM2 pathways intersect in microglia

Animal Model Studies

Knockout Mouse Models

ABCA7-deficient mice recapitulate several features of AD risk[@liu2022]:

Learning and memory deficits: Aged mice show impaired spatial memory
Aβ accumulation: Increased Aβ deposition in brain with aging
Lipid abnormalities: Altered brain lipid composition
Microglial dysfunction: Impaired phagocytic capacity

Rescue Studies

Restoring ABCA7 expression in knockout mice:

Partial reversal of cognitive deficits
Reduced Aβ accumulation
Restored microglial function

These studies support ABCA7 as a therapeutic target.

Interaction Network

ABCA7 participates in a network of interactions relevant to AD:

| Interactor | Interaction Type | Functional Consequence |
|-----------|------------------|----------------------|
| ApoE | Lipid transfer | Aβ clearance |
| ABCA1 | Functional cooperation | Redundant lipid transport |
| TREM2 | Pathway intersection | Microglial phagocytosis |
| CD33 | Antagonistic regulation | Phagocytosis balance |
| LDLR | Lipid binding | Cholesterol homeostasis |
| RAB proteins | Vesicle trafficking | Intracellular transport |

Therapeutic Implications

Targeting ABCA7

Given its role in AD pathogenesis, ABCA7 represents a promising therapeutic target:

| Strategy | Approach | Development Status |
|----------|----------|-------------------|
| Gene therapy | Viral delivery of functional ABCA7 | Preclinical |
| Small molecule activators | Enhance ABCA7 expression/activity | Discovery phase |
| Protein replacement | Direct ABCA7 protein delivery | Research stage |
| Modulator compounds | Allosteric modulation | Lead optimization |

Challenges

Several challenges face ABCA7-targeted therapies:

Blood-brain barrier: Therapeutic agents must penetrate the CNS

Timing: Intervention may be most effective in early disease stages

Specificity: Avoiding off-target effects on peripheral ABCA7

Isoform considerations: Multiple splice variants may have different functions

Peripheral effects: ABCA7 in immune cells affects systemic immunity

Biomarker Potential

ABCA7 has potential as a biomarker:

CSF ABCA7: Measurable levels in cerebrospinal fluid
Genetic testing: Risk variants can inform prognosis
Expression markers: ABCA7 expression in blood cells as a proxy

Epigenetic Regulation

ABCA7 expression is subject to epigenetic regulation[@wang2023]:

DNA methylation: Hypermethylation reduces ABCA7 expression in AD brain
Histone modifications: Acetylation and methylation affect promoter activity
Non-coding RNAs: miRNAs target ABCA7 mRNA
Environmental factors: Lifestyle and metabolic factors influence epigenetics

This epigenetic dysregulation provides a mechanistic link between environmental risk factors and ABCA7 function in AD.

Comparison with ABCA1

ABCA7 and ABCA1 are closely related transporters with both overlapping and distinct functions:

| Feature | ABCA7 | ABCA1 |
|---------|-------|-------|
| Primary expression | Brain (microglia), immune cells | Liver, peripheral cells |
| ApoE lipidation | Yes | Yes |
| Cholesterol efflux | Moderate | High |
| AD risk association | Strong | None |
| Therapeutic potential | High | Limited for AD |

The differential AD risk association suggests unique functions of ABCA7 in brain lipid homeostasis that are not compensated by ABCA1.

Key Research Findings

Williams et al. (2019) Nature: ABCA7 LoF variants increase AD risk by ~1.5 fold[@williams2019]

Kim et al. (2019) Nat Neurosci: ABCA7 deficiency impairs microglial phagocytosis[@kim2019]

Vasquez et al. (2020) J Neurosci: ABCA7 regulates brain ApoE and lipid homeostasis[@vasquez2020]

Stewart et al. (2021) Brain: ABCA7 regulates phagocytosis of Aβ in microglia[@stewart2021]

Liu et al. (2022) Acta Neuropathol Commun: ABCA7 deficiency enhances amyloid deposition[@liu2022]

Wang et al. (2023) Nat Aging: Epigenetic dysregulation of ABCA7 in AD[@wang2023]

Future Directions

Key questions remain about ABCA7 in AD:

What is the precise molecular mechanism of ABCA7 in Aβ clearance?
How does ABCA7 interact with other AD risk genes (TREM2, APOE)?
Can ABCA7 activators be developed as disease-modifying therapy?
What is the role of ABCA7 in tau pathology?
How do ABCA7 variants affect drug response?

Answering these questions will advance our understanding of ABCA7 in AD pathogenesis and inform therapeutic development.

Clinical Implications

Diagnostic Applications

ABCA7 genetic testing has several clinical applications:

Risk prediction: ABCA7 variants inform AD risk assessment alongside APOE and other genes
Early identification: Individuals with risk variants can be monitored earlier
Family screening: Relatives of carriers may benefit from genetic counseling
Differential diagnosis: ABCA7 variants help distinguish AD from other dementias

Therapeutic Development

ABCA7-targeted therapies offer disease-modifying potential:

Gene therapy: Viral delivery of functional ABCA7
Small molecule activators: Enhance ABCA7 expression or activity
Protein replacement: Direct ABCA7 protein delivery
Modulation of upstream pathways: Target regulators of ABCA7

Biomarker Potential

ABCA7 has potential as a biomarker:

Genetic testing: Risk variants can inform prognosis
Expression markers: ABCA7 expression in blood cells as a disease proxy
CSF biomarkers: ABCA7 protein levels in cerebrospinal fluid

Challenges

Several challenges face ABCA7-targeted approaches:

BBB penetration: Therapeutic agents must penetrate the CNS

Timing: Intervention may be most effective in early disease stages

Specificity: Avoiding off-target effects on peripheral ABCA7

Peripheral effects: ABCA7 in immune cells affects systemic immunity

Comparison with Other AD Risk Genes

ABCA7 interacts with multiple AD genetic risk factors:

| Gene | Interaction Type | Mechanism |
|------|-----------------|-----------|
| APOE | Synergistic | Combined effects on lipid metabolism |
| TREM2 | Additive | Microglial phagocytosis pathways |
| CD33 | Antagonistic | Opposing effects on phagocytosis |
| ABCA1 | Complementary | Overlapping lipid transport functions |
| CLU | Synergistic | Chaperone-mediated lipid transport |

The network of interactions suggests that targeting ABCA7 may have broad effects on AD pathogenesis.

Summary

ABCA7 represents a significant genetic risk factor for late-onset Alzheimer's disease. Key points include:

Genetic association: Common and rare variants increase AD risk by 1.5-2 fold
Molecular function: Lipid transporter critical for microglial function
Disease mechanisms: Affects Aβ clearance, neuroinflammation, and lipid homeostasis
Therapeutic potential: Activation of ABCA7 may provide disease-modifying effects
Research status: Active investigation of mechanisms and therapeutic approaches

Continued research on ABCA7 will advance our understanding of AD pathogenesis and develop novel therapeutic strategies.

Final Notes

ABCA7 research exemplifies the intersection of lipid metabolism, neuroinflammation, and neurodegeneration. The identification of ABCA7 as an AD risk gene has opened new avenues for understanding microglial biology and developing therapeutic interventions. Future studies will likely reveal additional mechanisms by which ABCA7 influences AD pathogenesis and identify novel therapeutic targets within the ABCA7 pathway.

Pathway Diagram

The following diagram shows the key molecular relationships involving ABCA7 (ATP-Binding Cassette Transporter A7) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ABCA7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-abca7
kg_node_id	ABCA7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-62d9ce353889
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-abca7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

70%

Debates

0

Incoming

14

Outgoing

45

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ABCA7 (ATP-Binding Cassette Transporter A7)

ABCA7 (ATP-Binding Cassette Transporter A7)

Pathway Diagram

ABCA7 (ATP-Binding Cassette Transporter A7)

Pathway Diagram

Overview

Function

Disease Associations

Alzheimer's Disease (AD)

Spastic Paraplegia

Expression

Allen Brain Atlas Data

Gene Expression

Single-Cell Expression

Brain Region Expression Levels

External Resources

Allen Brain Atlas Resources

Key Publications

Cross-links

See Also

External Links

Detailed Protein Structure

Mechanism of Lipid Transport

Lipid Efflux to ApoE

Genetic Variants and AD Risk

Common Variants

Rare Variants

Population-Specific Effects

ABCA7 and Microglial Function

Microglial Expression

Phagocytosis of Amyloid-Beta

Neuroinflammation

Animal Model Studies

Knockout Mouse Models

Rescue Studies

Interaction Network

Therapeutic Implications

Targeting ABCA7

Challenges

Biomarker Potential

Epigenetic Regulation

Comparison with ABCA1

Key Research Findings

Future Directions

Clinical Implications

Diagnostic Applications

Therapeutic Development

Biomarker Potential

Challenges

Comparison with Other AD Risk Genes

Summary

Final Notes

Pathway Diagram

💬 Discussion